Hemab Therapeutics Holdings

RA Capital’s 6.2 M‑share purchase of Hemab Therapeutics post‑IPO shows strong confidence in its neuromuscular pipeline and could stabilize stock as Phase‑2 trials approach.

Novo Holdings buys 4.18 M Hemab shares post‑IPO, backing its rare‑disorder pipeline and signaling long‑term confidence in Phase‑2 candidates HMB‑001 & HMB‑002.